Abstract: An industrial device supports device-level data modeling that pre-models data stored in the device with known relationships, correlations, key variable identifiers, and other such metadata to assist higher-level analytic systems to more quickly and accurately converge to actionable insights relative to a defined business or analytic objective. Data at the device level can be modeled according to modeling templates stored on the device that define relationships between items of device data for respective analytic goals (e.g., improvement of product quality, maximizing product throughput, optimizing energy consumption, etc.). This device-level modeling data can be provided to higher level systems together with their corresponding data tag values to high level analytic systems, which discovers insights into an industrial process or machine based on analysis of the data and its modeling data.

Abstract: The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of a calcium receptor-active compound and at least one pharmaceutically acceptable excipient, wherein the composition has a controlled dissolution profile. The present invention further relates to a method of manufacturing the pharmaceutical composition, as well as a method of treating a disease using the pharmaceutical composition.

Abstract: Disclosed are systems and techniques for providing a master health entity index and a data analysis mechanism designed for entity cohort discovery and entity profiling. The entity can be a healthcare facility that diagnoses or treats health conditions and diseases (e.g., hospital, clinic), individuals (e.g., providers, patients, caregivers), healthcare data (e.g., medical conditions, treatments, diagnostic studies, health outcomes), etc. For example, a data analysis mechanism may identify distinctive patient cohorts based on what happened to patients in a hospital and why the occurrence happened, glean insight from the activities of the distinctive patient cohorts, and assist with additional patients with the gleaned insight.

Abstract: Provided are a computer program product, system, and method for determining modified tracks to destage during a cache scan. A cache scan is initiated at a time interval to determine modified tracks to destage from a cache to the first or second storage. A modified track is processed during the cache scan. The modified track is destaged to the first storage in response to the modified track stored in the first storage. A determination is made as to whether there was a host write to the second storage since a previous cache scan in response to the modified track stored in the second storage. The modified track is destaged to the second storage in response to determining that there was a host write to the second storage since the previous cache scan.

Abstract: In one embodiment of split data migration in accordance with the present description, to migrate the data of a volume or other data unit which has been previously mirrored from a primary data storage system to a secondary data storage system, the data unit is split into two or more parts. One part is migrated from the primary data storage system to a migration target storage system, and another part is migrated from the secondary data storage system, to the same, common migration target storage system. In this manner, the migration workload of migrating a unit of data may be split between the primary and secondary storage systems, reducing the impact of migration data processing upon the primary storage system and reducing migration time. Other features and aspects may be realized, depending upon the particular application.

Abstract: The invention provides for methods of treating a dialysis patient that is hyporesponsive to erythropoietin stimulating agents (ESA) comprising administering soluble ferric triphosphate (SFP) composition and administering a dose of ESA that is significantly reduced compared to the dose of ESA required by a dialysis patient that is hyporesponsive to ESA that has not received SFP.

Abstract: Provided are a computer program product, system, and method for applying a machine learning algorithm to problem analysis in a code load operation of a data storage system. A code load driver is provided that receives code load operation information for an event during a code load operation in the storage system. The code load operation information indicates an error in the code load operation at a time of the event. A portion of the code load inform is processed by a machine learning to obtain a label indicating whether to halt the code load operation. In response to a label indicating the code load operation is to be halted, the code load operation is halted.

Abstract: The present invention relates to inhibitors of Transient Receptor Potential Channel 6 (TRPC6) protein activity. The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.

Abstract: Herein is provided a simple, reliable and accurate method for cellular analysis on hematology analyzers. In various aspects, the methods provide separation and/or differentiation between red blood cells (RBCs) and white blood cells (WBCs) by utilizing a fluorescent dye to selectively stain WBCs such that they emit stronger fluorescence signals. The method provides optimal detection limits on WBCs and RBCs, thereby allowing analysis of samples with sparse cellular concentrations. As few as one reagent may be used to prepare a single dilution for body fluid analysis, in order to simplify the body fluid analysis. Minimal damage to WBCs is attained using the lysis-free approach described in aspects of the disclosure.

Abstract: Provided are a method, system, and computer program product in which a storage controller receives a request from a host to migrate a source dataset comprising a plurality of tracks to a cloud storage. A plurality of readers are initiated to read the plurality of tracks of the source dataset in parallel, wherein each of the plurality of readers reads different tracks from the source dataset and transmits the tracks that are read from the source dataset to a migrator. For each track received by the migrator from the plurality of readers, the track is appended sequentially to a migrate dataset to be stored in the cloud storage. Metadata that indicates a mapping of tracks of the source dataset to tracks of the migrate dataset is generated.

Abstract: A storage controller receives a request from a host to generate a source dataset by downloading a cloud object corresponding to the source dataset from a cloud storage. A plurality of writers that execute in parallel determines from metadata that indicates a mapping of tracks of the source dataset to tracks of the cloud object, which track of the cloud object corresponds to which track of the source dataset, to generate the source dataset from the cloud object for storing in a storage drive coupled to the storage controller.

Abstract: A spare capacity status of each of multiple computing systems in a data center is monitored. Temporary workloads are assigned to these computing systems if there exists sufficient additional electrical power supply and capacity on power distribution lines. Thus, computing systems that are typically not productively used, such as those that are about to be decommissioned, have not yet been assigned for normal servicing, are reserved for special circumstances, or that are assigned to services that are currently in low demand, are temporarily used for productive data center purposes.

Abstract: The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of a calcium receptor-active compound and at least one pharmaceutically acceptable excipient, wherein the composition has a controlled dissolution profile. The present invention further relates to a method of manufacturing the pharmaceutical composition, as well as a method of treating a disease using the pharmaceutical composition.

Abstract: Provided are a computer program product, system, and method for determining modified tracks to destage during a cache scan. A cache scan is initiated at a time interval to determine modified tracks to destage from a cache to the first or second storage. A modified track is processed during the cache scan. The modified track is destaged to the first storage in response to the modified track stored in the first storage. A determination is made as to whether there was a host write to the second storage since a previous cache scan in response to the modified track stored in the second storage. The modified track is destaged to the second storage in response to determining that there was a host write to the second storage since the previous cache scan.

Abstract: Systems and methods for analyzing blood samples, and more specifically for performing a nucleated red blood cell (nRBC) analysis. The systems and methods screen a blood sample by means of fluorescence staining and a fluorescence triggering strategy, to identify nuclei-containing particles within the blood sample. As such, interference from unlysed red blood cells (RBCs) and fragments of lysed RBCs is substantially eliminated. The systems and methods also enable development of relatively milder reagent(s), suitable for assays of samples containing fragile white blood cells (WBCs). In one embodiment, the systems and methods include: (a) staining a blood sample with an exclusive cell membrane permeable fluorescent dye; (b) using a fluorescence trigger to screen the blood sample for nuclei-containing particles; and (c) using measurements of light scatter and fluorescence emission to distinguish nRBCs from WBCs.

Abstract: This disclosure relates to the use of Matrix-assisted laser desorption ionization (MALDI) mass spectrometry imaging (MSI) to assay tissue samples. Methods of analyzing a tissue sample may generally comprise generating sample ions directly from the tissue sample using a MALDI ionization source, receiving the ions into a mass spectrometer, identifying at least one esophageal tumor related compound in the sample from results from the mass spectrometer, comparing the at least one identified esophageal tumor related compound in the sample to one or more known esophageal tumor profiles, and identifying at least one condition related to the sample from the comparison of the at least one identified esophageal tumor related compound to the one or more known esophageal tumor profiles. The mass spectrometer may be a quadrupole mass spectrometer, a time of flight mass spectrometer, an Orbitrap mass spectrometer, or an ion trap mass spectrometer.

Abstract: Systems and methods for analyzing blood samples, and more specifically for performing a nucleated red blood cell (nRBC) analysis. The systems and methods screen a blood sample by means of fluorescence staining and a fluorescence triggering strategy, to identify nuclei-containing particles within the blood sample. As such, interference from unlysed red blood cells (RBCs) and fragments of lysed RBCs is substantially eliminated. The systems and methods also enable development of relatively milder reagent(s), suitable for assays of samples containing fragile white blood cells (WBCs). In one embodiment, the systems and methods include: (a) staining a blood sample with an exclusive cell membrane permeable fluorescent dye; (b) using a fluorescence trigger to screen the blood sample for nuclei-containing particles; and (c) using measurements of light scatter and fluorescence emission to distinguish nRBCs from WBCs.

Abstract: Methods, devices, and systems for automated cellular analysis of a body fluid sample are disclosed. The methods, devices, and systems apply watershed transform to data, generated by flowing a body fluid sample through a flow cytometer, to determine threshold(s) to be used for analysis of the data.

Abstract: A spare capacity status of each of multiple computing systems in a data center is monitored. Temporary workloads are assigned to these computing systems if there exists sufficient additional electrical power supply and capacity on power distribution lines. Thus, computing systems that are typically not productively used, such as those that are about to be decommissioned, have not yet been assigned for normal servicing, are reserved for special circumstances, or that are assigned to services that are currently in low demand, are temporarily used for productive data center purposes.

Abstract: The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of a calcium receptor-active compound and at least one pharmaceutically acceptable excipient, wherein the composition has a controlled dissolution profile. The present invention further relates to a method of manufacturing the pharmaceutical composition, as well as a method of treating a disease using the pharmaceutical composition.